Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania

Sabrina J Moyo1*, Said Aboud1, Mabula Kasubi2, Eligius F Lyamuya1, Samuel Y Maselle1

Abstract

Background: Published data on the existence and magnitude of extended spectrum beta-lactamase (ESBL) production in urinary pathogens in local setting is limited. The aim of the present study was to determine the prevalence of antimicrobial resistance and ESBL production among Escherichia coli and Klebsiella spp from urine samples in a tertiary hospital. This was a cross sectional study conducted at Muhimbili National Hospital in Dar es Salaam, Tanzania.

Findings: A total of 270 E.coli and Klebsiella spp urinary pathogens from children and adults isolated from January to March 2010 were included in the study. E. coli and Klebsiella spp isolates were tested for antimicrobial susceptibility by the Clinical and Laboratory Standard Institute’s disc diffusion method. These isolates were further screened for ESBL phenotype using cefotaxime and ceftazidime discs. Isolates with reduced sensitivity were confirmed using ESBL E-test strips. Of 270 isolates, 138 (51.1%) were E. coli and 132 (48.9%) were Klebsiella spp. ESBL was detected in 122 (45.2%) of all the isolates. ESBL- producing E. coli strains were significantly more resistance to cotrimoxazole (90.7%), ciprofloxacin (46.3%) and nalidixic acid (61.6%) than strains that did not produce ESBL (p < 0.05). Similarly, ESBL- producing Klebsiella spp strains were significantly more resistance to cotrimoxazole (92.6%), ciprofloxacin (25.0%), nalidixic acid (66.2%), and gentamicin (38.2%) than strains that did not produce ESBL (P < 0.05). Multi-drug resistance was found to be significantly (P < 0.05) more in ESBL producing isolates (90.5%) than non ESBL producers (68.9%). The occurrence of ESBL was significantly higher among isolates from inpatients than outpatients [95 (50.5%) vs. 27(32.9%)] (p = 0.008). The occurrence of ESBL was significantly higher among isolates from children than in adults [84 (54.9%) vs. 38(32.5%)] (p < 0.001).

Conclusions: High prevalence of ESBL-producing E. coli and Klebsiella spp strains was found among inpatients and children. Most of the ESBL- producing isolates were multi-drug resistant making available therapeutic choices limited. We recommend continued antibiotic surveillance as well comprehensive multi-center studies to address the emerging problem of ESBL-associated infections in order to preserve the continued usefulness of most antimicrobial drugs. Further more conducting molecular studies will help to evaluate the various ESBL types.

Background

Urinary tract infection (UTI) is the second most common infectious presentation in community practice. Worldwide, about 150 million people are diagnosed with UTI each year, costing the global economy in excess of 6 billion US dollars [1]. There have been significant changes in the antimicrobial resistance patterns of uropathogens over the years including resistance due to extended spectrum beta lactamase (ESBL)-producing pathogens [2-6]. The increasing prevalence of infections caused by antibiotic-resistant bacteria makes empirical treatment of these infections difficult [7]. Antibiotic resistance varies according to geographic locations and is directly proportional to the use and misuse of
antibiotics. Understanding the impacts of drug resistance is crucial as the changing rate of antibiotic resistance has a large impact on the treatment of UTI [3,4].

Production of ESBL is the most common amongst the mechanisms of resistance to third generation cephalosporins in Gram-negative bacilli [8]. While there are many published reports on ESBL-producing microorganisms in developed and developing countries [5,6,9], two previous studies which were done in 2005 confirmed the presence of ESBL-producing organisms in nosocomial and blood stream infections in a tertiary referral hospital in Dar es Salaam [10,11]. The current study aimed to determine the prevalence of antimicrobial resistance and ESBL production among E. coli and Klebsiella spp isolated from patients with UTI in a tertiary hospital.

Materials and methods

Study design and setting

This was a cross-sectional study conducted at Muhimbili National Hospital (MNH) in Dar es Salaam, Tanzania. Urinary isolates collected from January to March 2010 were included in the study.

Bacterial isolates

Urine samples received in the Central Pathology Laboratory (CPL) were plated on cysteine lactose electrolytes deficient (CLED) agar incubated at 37°C for 24 hours. A growth of >10⁵ colony forming units per mL of one type of organism was considered as significant bacteriuria. Identification of E. coli and Klebsiella spp isolates was done by observing colonial morphology on CLED medium. Lactose-fermenting colonies were further identified using standard biochemical tests as described previously [12].

Antibiotic susceptibility testing

E. coli and Klebsiella spp isolates were tested for antimicrobial susceptibility by the Clinical and Laboratory Standards Institute’s disc diffusion method, was formerly the National Committee for Clinical Laboratory Standards [13]. The following first and second line antibiotics were used in the testing: cefazidime (30 μg), ceftoxamine (30 μg), cotrimoxazole (25 μg), ampicillin (10 μg), gentamicin (15 μg), amikacin (30 μg), imipenem (10 μg), ciprofloxacin (5 μg), nalidixic acid (30 μg), and nitrofurantoin (300 μg). Multi-drug resistance was defined as resistance to three or more different antimicrobial agents.

Detection of ESBL

E. coli and Klebsiella spp isolates were screened for ESBL phenotype. Isolates with reduced susceptibilities to ceftazidime (zone diameter of <27 mm) and/or ceftazidime (zone diameter of <22 mm) were provisionally regarded as ESBL-producing pathogens according to guidelines for laboratory detection of ESBL from Clinical and Laboratory Standards Institute [13]. ESBL E-test strips (Biome-ieux, Solna, Sweden) were used for confirmation of ESBL production. Minimum inhibitory concentrations (MIC) of cefotaxime and ceftazidime with and without clavulanic acid were determined. The inoculated plates were incubated for 16-18 hours at 37°C.

ESBL results were read either as MIC values or observation of ‘phantom’ zones or deformation of inhibition ellipses according to manufacturer instructions. Reduction of MIC by at least three two-fold dilutions in the presence of clavulanic acid was indicative of ESBL production. Deformation of ellipses or the presence of a ‘phantom’ zone was also indicative of ESBL production even if the MIC ratio was <8 or could not be read. Isolates were reported as having ESBL phenotype if one or more of the ESBL E-tests were positive. E. coli ATCC 25922 was used as ESBL negative control and K. pneumoniae ATCC 700603 was used as ESBL positive reference strain.

Statistical analysis

Statistical Package for the Social Sciences (SPSS) version 17.0 was used for data analysis. Contingency table analysis was done by a chi-square test or two-tailed Fisher’s exact test where applicable. A p-value of less than 0.05 was considered as statistically significant.

Ethical considerations

The study was carried out in accordance with existing ethical guidelines. Ethical clearance was obtained from the Senate Research and Publications Committee of Muhimbili University of Health and Allied Sciences, Dar es Salaam.

Results

During the study period, a total of 270 E. coli and Klebsiella spp were isolated. The urinary pathogens were isolated more from female (54.4%) than male (45.6%) patients (Table 1). Of the total number of bacterial isolates obtained 56.7% were from paediatric patients while 43.3% were from adults. Of the 270 isolates, 138 (51.1%) were E. coli and 132 (48.9%) were Klebsiella spp. There was significantly higher proportion of bacteria isolated from inpatients (69.6%) than outpatients (30.4%) (p = 0.008).

The frequency of antimicrobial resistance for 11 selected antimicrobial agents against E. coli and Klebsiella spp UTI pathogens are summarized in Table 2 and 3. ESBL was detected in 122 (45.2%) of all the isolates. Among E. coli isolates 39.1% were ESBL producers. E. coli showed high rate of resistance was seen to
ampicillin (96.4%), followed by cotrimoxazole (80.4%) and amoxicillin/clavulanic acid (69.6%) (Table 2). Resistance to cefotaxime and ceftazidime was 50.7% and 49.3%, respectively. *E. coli* showed least rate of resistance to imipenem (6.5%). ESBL- producing *E. coli* were significantly more resistant to cotrimoxazole (90.7%), ciprofloxacin (46.3%) and nalidixic acid (61.6%) than non-ESBL *E. coli* producing strains (p < 0.05). Multi-drug resistance was significantly higher among ESBL- producing *E. coli* strains than non-ESBL producing *E. coli* (87.0% vs. 54.8%) p < 0.001.

Among isolates of *Klebsiella spp*, 51.1% were ESBL-producers. *Klebsiella spp* showed high rate of resistance to ampicillin (98.5%), followed by cotrimoxazole (82.6%) and amoxicillin/clavulanic acid (78.0%) (Table 3). Resistance to cefotaxime and ceftazidime was 65.9% and 65.9%, respectively. *Klebsiella spp* showed least rate of resistance to imipenem (6.8%). ESBL- producing *Klebsiella spp* strains were significantly more resistant to cotrimoxazole (92.6%), ciprofloxacin (25.0%), nalidixic acid and gentamicin (38.2%) than non-ESBL producing strains (p < 0.05). Other antimicrobial agents for which ESBL-producing strains showed significant resistance included cefotaxime (100%), ceftazidime (100%), cotrimoxazole (92.6%), ciprofloxacin (25.0%), nalidixic acid (66.2%) and gentamicin (38.2%) (p < 0.05). Multi-drug resistance was significantly higher among ESBL- producing *Klebsiella spp* strains than non-ESBL producing *Klebsiella spp* (82.4% vs. 35.9%) p < 0.001.

The occurrence of ESBL was found to be significantly higher among isolates from inpatients than outpatients [95 (50.5%) vs. 27(32.9%)] (p = 0.008). The rate of ESBL production was also significantly higher among isolates from children than in adults [84 (54.9%) vs. 38 (32.5%)] (p < 0.001).

### Discussion

Knowledge on local antimicrobial resistance trends among urinary isolates is important not only in guiding clinicians to prescribe appropriate antibiotics but also for evidence based recommendations in empirical antibiotic treatment of UTI. The current study described the antimicrobial resistance rates including detection of ESBL among *E. coli* and *Klebsiella spp* urinary isolates which are the predominant ESBL- producers.

In the current study the antimicrobial resistance rate of both *E. coli* and *Klebsiella spp* isolates was high to the first line antimicrobial agents such as ampicillin, cotrimoxazole, and amoxicillin/clavulamic acid. High resistance to first line drugs found in the current study is similar to other studies in developing countries [11,14,15]. The observation may be due to wide use of

### Table 1 Distribution of bacteria isolates according to patient age and sex, wards and bacterial species (n = 270)

| Characteristics          | Number | Percentage |
|--------------------------|--------|------------|
| Age                      |        |            |
| Children                 | 153    | 56.7       |
| Adults                   | 117    | 43.3       |
| Sex                       |        |            |
| Male                     | 123    | 45.6       |
| Female                   | 147    | 54.4       |
| Wards                    |        |            |
| Out patients             | 82     | 30.4       |
| In patients              | 188    | 69.6       |
| Pathogens isolated       |        |            |
| *E. coli*                | 138    | 51.1       |
| *Klebsiella spp*         | 132    | 48.9       |
| ESBL producing *E. coli* | 54     | 39.1       |
| ESBL producing *Klebsiella spp* | 68     | 51.5       |

### Table 2 Antimicrobial resistance of ESBL and non-ESBL producing *E. coli* in Dar es Salaam, Tanzania (n = 138)

| Antibiotic               | Resistance n (%) | ESBL- Producing n = 54 | Non-ESBL producing n = 84 | P-value* |
|--------------------------|------------------|------------------------|--------------------------|---------|
| Cefotaxime               | 70 (50.7%)       | 50 (92.6)              | 20 (23.8)                | <0.001  |
| Ceftazidime              | 68 (49.3%)       | 51 (94.4)              | 17 (20.2)                | <0.001  |
| Ampicillin               | 133 (96.4%)      | 53 (98.1)              | 80 (95.2)                | 0.37    |
| Amoxycillin/clavulanic acid | 96 (69.6%)     | 39 (72.2)              | 57 (67.9)                | 0.6     |
| Imipenem                 | 9 (6.5%)         | 4 (7.4)                | 5 (6.001)                | 0.7     |
| Amikacin                 | 15 (10.9%)       | 6 (11.1)               | 9 (10.7)                 | 0.9     |
| Gentamicin               | 53 (38.4%)       | 26 (48.1)              | 27 (32.1)                | 0.06    |
| Nalidixic acid           | 57 (41.3%)       | 28 (51.6)              | 29 (34.5)                | 0.04    |
| Ciprofloxacin            | 42 (30.4%)       | 25 (46.3)              | 17 (20.2)                | 0.001   |
| Nitrofurantoin           | 31 (22.5%)       | 11 (20.4)              | 20 (23.8)                | 0.6     |
| Cotrimoxazole            | 111 (80.4%)      | 49 (90.7)              | 62 (73.8)                | 0.014   |
| Multi drug resistance    | 93 (67.4%)       | 47 (87.0)              | 46 (54.8%)               | <0.001  |

*P value is for a comparison of resistance among ESBL-producers with that among non-producers.*
these drugs empirically because they are relatively cheap and also by being oral antibiotics they are easy to administer. In addition, resistance to cotrimoxazole may be due to the fact that this drug is widely used for prophylaxis against opportunistic infections associated with HIV whose prevalence in our setting is high. The high level of resistance to amoxicillin/clavulanic acid is in keeping with the previous report in the same hospital [11] as well as studies conducted in other countries [16]. These findings suggest that beta-lactam/beta-lactamase inhibitor combination may not be useful in our setting for the treatment of UTI. A previous study has documented treatment failures due to the use of beta-lactam/beta-lactamase inhibitor combinations for infections caused by ESBL-producing organisms [17].

We demonstrated a high prevalence of ESBL production by E. coli (39.1%) and by Klebsiella spp (51.5%) urinary isolates at MNH. These findings are higher than those reported five years ago in the same hospital [10,11]. In the previous studies, 25% and 17% of E. coli and Klebsiella spp, respectively, isolated from septicaemic patients [10] and 28.2% of enteric pathogens from intensive care unit (ICU) patients [11] were ESBL-producers. Several possible reasons may have contributed to the high prevalence of ESBL-producing urinary isolates. Since UTI is relatively common, wide spread use of broad-spectrum antibiotics due to inappropriate prescribing practices are most likely. In addition, the hospital does not perform routine screening of ESBL production in clinical isolates and hence there are no guidelines for isolation of patients carrying these ESBL-producing strains which could have resulted in the spread of these strains.

ESBL-producing E. coli and Klebsiella spp in this study showed a significantly high rate of resistance to non-beta lactam antibiotics. These findings are similar to those reported by others [11,18-20]. This observation may be explained by the fact that ESBL are plasmid-mediated enzymes which are transferable between one bacterium to another and such transferable plasmids also code for resistance determinants to antimicrobial agents other than beta-lactams [21]. ESBL-producing E. coli and Klebsiella spp showed significantly high resistance to ciprofloxacin. These findings are higher than the resistance found by Blomberg et al in the same study setting [10,11]. The increased resistance implies that ciprofloxacin should be used with caution.

Our findings show that carbapenem are the most effective and drug of choice against both ESBL and non ESBL-producing E. coli and Klebsiella spp as more than 90% of isolates were sensitive to imipenem. Although imipenem showed high rate of sensitivity; 6.5% and 6.8% isolates of E. coli and Klebsiella spp, respectively, were resistant. Reduced imipenem susceptibility has been described in E. coli with CTX-M-type ESBL [22]. CTX-M type ESBL has been described before in our settings [10,11], which in part could explain the observation in the current study. Therefore further studies are needed for molecular characterization of ESBL isolates circulating in our setting. With sensitivity rate of 79% for ESBL-producing isolates nitrofurantoin might be the only useful oral antibiotic in the treatment of UTI in the local setting, at least in a tertiary health facility.

There was significantly higher proportion of ESBL-producing isolates among isolates from in-patients than out-patients (p < 0.05). This finding is similar to that observed by Khanfar et al [16] and points to the possibility of nosocomial acquisition of UTI due to ESBL pathogens. These findings have significant implications for empirical management of patients with UTI using third generation cephalosporins.

### Table 3 Antimicrobial resistance of ESBL and non-ESBL producing Klebsiella spp in Dar es Salaam, Tanzania (n = 138)

| Antibiotic   | Resistance n (%) | ESBL-Producing n = 68 | Non-ESBL producing n = 64 | P-value* |
|--------------|------------------|-----------------------|--------------------------|----------|
| Cefotaxime   | 87(65.9%)        | 68(100)               | 19(29.7)                 | <0.001   |
| Cefazidime   | 87(65.9%)        | 68(100)               | 19(29.7)                 | <0.001   |
| Ampicillin   | 130(98.5%)       | 67(98.5)              | 63(98.4)                 | 0.9      |
| Amoxicillin/ clavulanic acid | 103(78.0%) | 57(83.8) | 46(71.9) | 0.09 |
| Imipenem     | 9(6.8%)          | 6(8.8)                | 3(4.7)                   | 0.2      |
| Amikacin     | 28(21.2%)        | 17(25.0)              | 11(17.2)                 | 0.2      |
| Gentamicin   | 38(28.8%)        | 26(38.2)              | 12(18.8)                 | 0.008    |
| Nalidixic acid | 65(49.2%)   | 46(66.2)              | 20(31.2)                 | <0.001   |
| Ciprofloxacin | 25(18.9%)    | 17(25.0)              | 18(28.1)                 | 0.04     |
| Nitrofurantoin | 24(18.2%)  | 14(20.6)              | 11(17.2)                 | 0.5      |
| Cotrimoxazole | 109(82.6%) | 63(92.6)              | 46(71.9)                 | 0.001    |
| Multi drug resistance | 79(59.8%) | 56(82.4) | 23(35.9) | <0.001 |

*P value is for a comparison of resistance among ESBL-producers with that among non-Producers.
Infections caused by ESBL-producing pathogens have been reported to be associated with risk factors such as age. In the current study, ESBL production was significantly higher in children (68.9%) than adults (31.1%) \((p < 0.05)\). These findings compare well with those reported elsewhere \([18,23]\).

**Conclusions**

High prevalence of ESBL-producing *E. coli* and *Klebsiella spp* strains was found among inpatients and children. Most of the ESBL-producing isolates were multi-drug resistant making available therapeutic choices limited. We recommend continued antibiotic surveillance as well as comprehensive multi-center studies to address the emerging problem of ESBL-associated infections in order to preserve the continued usefulness of most antimicrobial drugs. Further more conducting molecular studies will help to evaluate the various ESBL types.

**Authors' contributions**

SM, SA, MK, EFL and SYM participated in the design of the study. SM oversaw the implementation of the study. SM, SA and MK were responsible for the laboratory testing. SM drafted the report and all co-authors participated in revising the report. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Received:** 3 August 2010  **Accepted:** 24 December 2010  **Published:** 24 December 2010

**References**

1. Gonzalez CM, Schaeffer AJ. Treatment of urinary tract infection: what's old, what's new, and what works. *World J Urol* 1999, 17:372-382.
2. Stamm WE, Stapleton AE. Approach to the patient with urinary tract infection. In *Infectious Diseases*, 2nd edition. Edited by: Gorbach SL, Bartlett JG, Blacklow NR. Philadelphia: WB Saunders; 1998:1270-1272.
3. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women. A nationwide analysis. *Clin Infect Dis* 2001, 33:89-94.
4. Gales AC, Jones RN, Gordon KA, Sader HS, Wilkie WW, Beach ML, Pfaffer MA, Doerr GV. Activity and spectrum of 22 antimicrobial agents tested against urinary tract pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). *J Antimicrob Chemother* 2000, 45:295-303.
5. Tankhiwale SS, Jha, Ashok SK, Ahamed S, Hassan U. Evaluation of extended spectrum beta lactamase in urinary isolates. *Indian J Med Res* 2004, 120:553-556.
6. Mohammed A, Mohammed S, Asad UK. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. *Ann Clin Microbiol Antimicrob* 2007, 6:4.
7. Steineke DT, Seaton RA, Phillips G, MacDonald TM, Davey PG. Prior trimethoprim use and trimethoprim-resistant urinary tract infection: a nested case-control study with multivariate analysis for other risk factors. *J Antimicrob Chemother* 2001, 47:781-787.
8. Black JA, Moland ES, Thomson KS. AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases. *J Clin Microbiol* 2005, 43:1110-1113.
9. Manges AR, Natarajan P, Solberg GD, Dietrich FS, Riley LW. The changing prevalence of drug-resistant *Escherichia coli* clonal groups in a community: evidence for community outbreaks of urinary tract infections. *Epidemiol Infect* 2006, 134:425-431.
10. Blomberg B, Jureen R, Manji KP, Tamim BS, Mvakagile DS, Ursara WK, Fataki M, Msangi V, Telfevik MG, Maselle SY, Langeland N. High rate of fatal cases of pediatric causation by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. *J Clin Microbiol* 2005, 43:745-749.
11. Nduguille F, Jureen R, Hirthag S, Ursara W, Langeland N. Extended Spectrum beta-Lactamases among Gram-negative bacteria of nosocomial origin from an Intensive Care Unit of a tertiary health facility in Tanzania. *BMC Infect Dis* 2005, 5:86.
12. Murray, Baron, Pfaller, Tenover. *Manual of Clinical Microbiology* 6 edition. American Society of Microbiology Press, Washington DC, 1999.
13. Clinical and Laboratory Standards Institute. *Ninth edition* Clinical and Laboratory Standards Institute, Wayne, PA. Performance standards for antimicrobial disk susceptibility tests. Approved standard, 2006.
14. Ahmed AA, Osman H, Mansour AK, Musa HA, Ahmed AB, Karar Z, Hassan HS. Antimicrobial agent resistance in bacterial isolates from patients with diarrhea and urinary tract infection in Sudan. *Am J Trop Med Hyg* 2000, 63:259-263.
15. Hima-Lerible H, Ménard D, Talarmin A. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic. *J Antimicrob Chemother* 2003, 51:192-194.
16. Khanfar HS, Bindayna KM, Senov AC, Botta GA. Extended spectrum beta-lactamases (ESBL) in *Escherichia coli* and *Klebsiella pneumoniae*: trends in the hospital and community settings. *J Infect Dev Ctries* 2009, 3:295-299.
17. Peterson LR. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam. *Clin Microbiol Infect* 2008, 1:181-184.
18. Mehrgan H, Arab-Halvaii Z. Highly prevalent of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* in a tertiary care hospital in Tehran, Iran. *J Infect Dev Ctries* 2010, 4:132-138.
19. Alhambra A, Cuadros JM, Cacho J, Gómez-Garcés JL, Alós JL. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. *J Antimicrob Chemother* 2004, 53:1090-1094.
20. Procop GW, Tuohey MJ, Wilson DA, Williams D, Hadsyannis E, Hall GS. Cross-class resistance to non-beta-lactam antimicrobials in extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *Am J Clin Pathol* 2003, 120:265-267.
21. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. *Am J Infect Control* 2006, 34:20-28.
22. Lartigue MF, Poirel L, Poyart C, Réglier-Poupet H, Nordmann P. High rate of fatal cases of pediatric causation by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. *J Clin Microbiol* 2005, 43:745-749.
23. Jabeen K, Zafar A, Hasan R. Antimicrobial resistance among producers and non-producers of extended spectrum beta-lactamases in urinary isolates at a tertiary Hospital in Tanzania. *BMC Research Notes* 2010, 3:348.